Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3669-3676

  Fabbrini, Paolo ^a,b   Schilte, Margot N ^b   Zareie, Mammad ^b   Ter Wee, Piet M ^b   Keuning, Eelco D ^b   Beelen, Robert H J ^b   Van Den Born, Jaap ^b,c  

^a SAN GERARDO HOSPITAL   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Celecoxib; Fibrosis; Peritoneal dialysis; Ultrafiltration failure

Indexed keywords

AQUAPORIN 1; CELECOXIB; CYCLOOXYGENASE 2; HYALURONIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; PERITONEAL DIALYSIS FLUID; PROSTAGLANDIN E2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR PARAMETERS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; INFLAMMATION; LEUKOCYTE COUNT; LYMPHANGIOGENESIS; MALE; NONHUMAN; OMENTUM; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; RETROPERITONEAL FIBROSIS; TREATMENT FAILURE; ULTRAFILTRATION;

ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; HEMODIAFILTRATION; MALE; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PYRAZOLES; RATS; RATS, WISTAR; SULFONAMIDES; TREATMENT FAILURE;

EID: 71049132749     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp384     Document Type: Article

References (36)

1. De Vriese AS, Mortier S, Lameire NH. What happens to the peritoneal membrane in long-term peritoneal dialysis? Perit Di al Int 2001; 21(Suppl 3): S9-S18
2. Mackenzie R, Holmes CJ, Jones S et al. Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients. Kidney Int 2003; 88(Suppl): S84-S93
3. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-7916
4. RomanoM,ClariaJ.Cycloxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implication for cancer therapy. F A S E B J 2003; 17: 1986-1995
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676
6. Yuan A, Pan-Chyr Y, Kwen-Tay L. Tumoral COX-2 overexpression correlates with vascular endothelial growth factor (VEGF) expression and angiogenesis, and associated with short survival and early relapse in non small cell lung cancer. Proc Am Assoc Cancer Res 2003; 44: 928-934
7. Daniel TO, Liu H, Morrow JD et al. Thromboxane A2 is a mediator of cyclooxygenase-2 dependent endothelial migration and angiogenesis. Cancer Res 1999; 59: 4574-4577
8. Inoue H, Takamori M, Shimoyama Y et al. Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulatingfactor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 2002; 136: 287-295
9. Murohara T, Horowitz JR, Silver M et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacycline. Circulation 1998; 97: 99-107
10. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R et al. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 1997; 420: 28-32
11. Planagumà A, Claria J, Miquel R et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanism involving non parenchymal cell apoptosis and PPARy activation. FA S E B J 2005; 19: 1120-1122
12. Liu H, Peng Y, Liu F et al. A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells. Cell Biol Int 2007; 31: 508-515
13. Topley N, Petersen MM, Mackenzie R et al. Human peritoneal mesothelial cell prostaglandin synthesis: induction of cyclooxyge-nase mRNA by peritoneal macrophage-derived cytokines. Kidney Int 1994; 46: 900-909
14. Shanmugam N, Gaw Gonzalo IT, Natarajan R. Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. Diabetes 2004; 53: 795-802
15. Saed GM, Munkarah AR, Diamond MP. Cyclooxygenase-2 is expressed in human fibroblasts isolated from intraperitoneal adhesions but not from normal peritoneal tissues. Fertil Steril 2003; 79: 1404-1408
16. Aroeira LS, Lara-Pezzi E, Loureiro J et al. Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane. J Am Soc Nephrol 2009; 20: 582-592
17. Iniguez MA, Rodriguez A, Volpert OV et al. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003; 9: 73-78
18. Grösch S, Maier TJ, Schiffmann S et al. Cyclooxygenase-2 (COX-2) independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736-747
19. Hekking LH, Zareie M, Driesprong BA et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 2001; 12: 2775-2786
20. Paulson SK, Zhang JY, Breau AP et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 2000; 28: 514-521
21. Fosang AJ, Hey NJ, Carney SL et al. An ELISA plate-based assay for hyaluronan using biotinylated proteoglycan G1 domain (HA-binding region). Matrix 1990; 10: 306-313
22. Zareie M, Hekking LH, Welten AG et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18: 2629-2637
23. Whitaker D, Papadimitriou JM, Walters MN. The mesothelium; techniques for investigating the origin, nature and behaviour of mesothelial cells. J Pathol 1980; 132: 263-271
24. Zareie M, Fabbrini P, Hekking LH et al. Novel role for mast cells in omental tissue remodeling and cell recruitment in experimental peritoneal dialysis. J Am Soc Nephrol 2006; 17: 3447-3457
25. Claria J, Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des 2005; 11: 3431-3447
26. Jeon SH, Chae BC, Kim HA et al. Mechanisms underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J Leukocyte Biol 2007; 81: 557-566
27. Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995; 82: 864-873
28. Andersohn F, Suissa S, Garbe E. Use of first-and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113: 1950-1957
29. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279-286
30. Leypoldt JK. Solute transport across the peritoneal membrane. J Am Soc Nephrol 2002; 13(Suppl 1): S84-S91
31. Rippe B, Venturoli D. Simulations of osmotic ultrafiltration failure in CAPD using a serial three-pore membrane/fiber matrix model. Am J Physiol Renal Physiol 2007; 292: F1035-F1043
32. Timoshenko AV, Chakraborty C, Wagner GF et al. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006; 94: 1154-1163
33. Schilte MN, Loureiro J, Keuning ED et al. Long-term intervention with heparins in a rat model of peritoneal dialysis. Perit Di al Int 2009; 29: 26-35
34. Stoenoiu MS, Ni J, Verkaeren C et al. Corticosteroids induce expression of aquaporin-1 and increase transcellular water transport in rat peritoneum. J Am Soc Nephrol 2003; 14: 555-565
35. Sakurada T, Kuboshima S, Ogimoto G et al. Aquaporin-1 is recruited to the plasma membrane by hyperosmotic stimuli via a protein kinase A-dependent pathway in rat peritoneal mesothelial cells. Adv Perit Dial 2004; 20: 37-42
36. Solomon SD, McMurray JJ, Pfeffer MA et al. Adenoma Prevention with Celecoxib (APC) Study Investigators: cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080